1. Introduction {#sec1}
===============

Periampullary adenocarcinoma (PAAC) including adenocarcinoma (AC) of pancreatic head, the distal common bile duct (CBD), the second portion of the duodenum, and the ampulla of Vater, it accounts for approximately 0.2% of all gastrointestinal tract tumors. In recent years, the occurrence of periampullary tumors has an increasing trend although is relatively uncommon neoplasm \[[@bib1], [@bib2], [@bib3]\].

Pancreaticoduodenectomy (PD) is the treatment of choice for PAAC, however, only 10--15% are resectable at the time of diagnosis. Patient survival after radical resection of periampullary tumors greatly varies, the different biology of the tumor origin could result to some degree into the difference of prognosis \[[@bib4], [@bib5], [@bib6]\].

Several clinicopathological factors, such as tumor size, resection margin, cell differentiation, lymph node metastasis, perineural and perivascular invasion have been comprehensively studied for determining survival outcome after PD for periampullary cancers \[[@bib7], [@bib8], [@bib9]\]. Lymphovascular invasion and perineural infiltration in the specimens post-Whipple were reported to be associated with reduced 5-year survival in patients with PAAC \[[@bib10], [@bib11], [@bib12]\].

Pancreaticoduodenectomy surgery is associated with high morbidity and mortality, therefore it is important to determine which patient can receive benefits from surgery to avoid unnecessary intervention and to facilitate treatment planning of neoadjuvant and adjuvant treatments \[[@bib12],[@bib13]\]. This study aimed to investigate the prognostic factors for long-term survival in resectable PAAC.

2. Patients and methods {#sec2}
=======================

We conducted a retrospective study to patients who underwent PD for PAAC between January 2010 to January 2019 at the department of Hepato-pancreato-biliary surgery, National Liver Institute, Menoufia University, Egypt. Data were retrieved from the prospectively collected pancreatic database and patients\' medical files, after local Institutional Review Board approval. The research goes with the standards of the Declaration of Helsinki and ethical guidelines and was registered in the clinical trial no ChiCTR2000034782. The study was written in line with the Strengthening the Reporting of Cohort Studies in Surgery (STROCSS) criteria \[[@bib14]\]. Patients with confirmed PAAC in the pathological study of the specimen after surgery were included in our study. Other pathological types of lesions after PD were excluded from the study. Data on preoperative, Intraoperative, and postoperative care were collected and analyzed.

2.1. Preoperative evaluation {#sec2.1}
----------------------------

Magnetic resonance image (MRI) or multi-detector abdominal computed tomography (CT) with three-dimensional reconstructions are used to evaluate the periampullary tumors and its relation to vascular structures. Endoscopic ultrasound was done for cases with suspicious diagnosis and for determining the relation of the mass with the surrounding vessels. Preoperative endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous trans-hepatic drainage (PTD) was done in case of cholangitis or delayed surgery.

2.2. Surgical procedure and pathological evaluation {#sec2.2}
---------------------------------------------------

Laparotomy was done by bilateral subcostal or midline incision. Patients underwent classical Whipple\'s operation or pylorus-preserving pancreaticoduodenectomy (PPPD). Pancreatic reconstruction was done by either pancreatico-jejunostomy (PJ) or pancreatico-gastrostomy (PG). Wedge or segmental resection of the portal vein or superior mesenteric vein was performed if a pancreatic head mass was inseparable from the vein. The histopathological features of the specimens were analyzed according to; tumor origin, size, grade, resection margin, lymph node (LN) invasion, perineural and lymphovascular invasion. According to Royal College of Pathologists\' guidelines on reporting histological outcomes after major pancreatic resections \[[@bib15]\], perineural infiltration was considered positive if tumor cells were identified within the perineural space and/or nerve fibers whereas lymphovascular invasion was defined as the presence of tumor within an endothelial lined or lymphatic space ([Fig. 1](#fig1){ref-type="fig"})**.**Fig. 1a) Poorly differentiated pancreatic ductal adenocarcinoma (H&E 100x). b) Positive lymph node invasion of Pancreatic ductal adenocarcinoma (black arrows) (H&E 4x). c) Lymph vascular invasion of pancreatic ductal adenocarcinoma (H&E 100x). d) Extensive perineural invasion of well differentiated pancreatic ductal adenocarcinoma (black arrows) (H&E 4x).Fig. 1

2.3. Postoperative follow-up {#sec2.3}
----------------------------

Follow-up has been arranged in the outpatient clinic or through personal contact, every three months in the first year, in the second and third years every six months then yearly later on. The follow-up was from the date of surgery until July 2020 with a median period of follow up 39 months. Long-term survival was considered ≥ 5-year of survival. Postoperative complications were classified according to the Dindo-Clavien grading system \[[@bib16]\]. Postoperative pancreatic fistula (POPF), post pancreatectomy hemorrhage (PPH), and delayed gastric emptying (DGE) were defined and graded according to the International Study Group for Pancreatic Surgery (ISGPS) \[[@bib17], [@bib18], [@bib19]\].

2.4. Statistical analysis {#sec2.4}
-------------------------

Statistical analysis was done using SPSS 23 (SPSS Inc., Chicago, IL). Fisher\'s exact or Chi-square X^2^ test was used for categorical variables comparison. For comparing 2 or more continuous variables, the Mann-Whitney *U* test or Kruskal-Wallis test was used respectively. Overall survival (OS) rates in different groups were done by using the Kaplan-Meier method, while the survival rate comparison was applied by the Log-rank test. Cox\'s regression model was appraised for the multivariate analysis in case of any significant variable in the univariate analysis. *P-*value was considered to be statistically significant if less than 0.05.

3. Results {#sec3}
==========

3.1. Demographic and preoperative data of the patients {#sec3.1}
------------------------------------------------------

During this study, 137 patients underwent PD for PAAC. Patient demographics and characteristics are shown in [Table 1](#tbl1){ref-type="table"}. Of these patients 84 (61.3%) were male and the mean age was 56.8 years. The main complaint was jaundice in 112 patients (81.8%). Preoperative biliary drainage was done in 58 patients (42.3%); by ERCP in 42 patients and PTD in 16 patients.Table 1Demographic and preoperative data of the patients.Table 1VariablesPatients with PD (n = 137)**Age (y)**mean ± SD56.8 ± 12.9(range)(28--82)**Sex**Male84 (61.3%)Female53 (38.7%)**Bodyweight**mean ± SD65 ± 17(range)(59--105)**Co-morbidities**DM59 (43.1%)HTN and/or IHD42 (30.7%)Associated HCV or HBV11 (8%)Chest problem13 (9.5%)**History of smoking**Yes62 (45.3%)No75 (54.7%)**Main symptoms**Jaundice112 (81.8%)Itching46 (33.6%)Loss of weight62 (45.3%)Anorexia64 (46.7%)Abdominal pain73 (53.3%)Vomiting57 (41.6)**Preoperative total bilirubin (mg/dl)**mean ± SD12.7 ± 5.4(range)(2.1--29)**Albumin (g/dl)**mean ± SD3.7 ± 0.6(range)(3.2--5)**INR**mean ± SD1.1 ± 0.4(range)0.9--1.5**CA 19-9** (U/mL)mean ± SD512 ± 1247(range)(4--5710)**CEA** (U/mL)mean ± SD6.2 ± 15.3(range)1--125**Preoperative biliary drainage**Yes58 (42.3%)no79 (57.7%)[^1]

3.2. Operative, pathological, postoperative data and complications {#sec3.2}
------------------------------------------------------------------

Seventy-nine patients (57.7%) underwent PPPD and 65.7% patients had PDAC in the pathological study. According to the type of pancreatic reconstruction; PJ was done in 108 patients (78.8%), mainly by duct to mucosa in 68 patients, whereas PG was done in 29 patients (21.2%). Seventeen patients (12.4%) underwent vascular reconstruction; PV or SMV reconstruction was done by lateral venoraphy in 10 patients and end to end primary repair using 6/0 proline in 7 patients. Postoperative pancreatic fistula was found in 26 patients (19%) and mainly grade A POPF. Other operative pathological and postoperative data were shown in [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}.Table 2Operative and pathological data.Table 2VariablesPatients with PD (n = 137)**Type of operation**PPPD79 (57.7%)Classic Whipple58 (42.3%)Pancreatic textureFirm57 (41.6%)Soft80 (58.4%)**Type of pancreatic reconstruction**Pancreaticogastrostomy29 (21.2%)Pancreaticojejunostomy108 (78.8%)-invagination40 (37%)-duct to mucosa68 (63%)**Pancreatic duct stent**Yes46 (33.6%)No91 (66.4%)**Vascular reconstruction**Yes17 (12.4%)No120 (87.6%)**Operative time** (min)mean ± SD450 ± 70(range)(280--560)Operative blood lossmean ± SD900 ± 550(range)(300--2200)**Blood transfusion** (unit)mean ± SD1.5 ± 1(range)(0--5)**Site of the tumor**Pancreatic head90 (65.7%)Ampullary31 (22.6%)Lower CBD10 (7.3%)Duodenum6 (4.4%)**Pathological maximum tumor diameter**Mean ± SD3.4 ± 1.6(Range)(1.4--9)**Tumor stage**T112 (8.8%)T257 (41.6%)T352 (38%)T416 (11.6%)**Tumor differentiation**Well/moderate103 (75.2%)Poor34 (24.8%)**Positive lymph node**Yes58 (42.3%)No79 (57.7%)**Number of LN dissection mean (range)5(2-24)Number of LN infiltration mean (range)**0(0-5)LN ratio079 (57.7%)\<0.218 (13.1%)0.2--0.426 (19%)\>0.414 (10.2%)**lymph vascular invasion**Yes62 (45.3%)No75 (54.7%)**Perineural invasion**Yes51 (37.2%)No86 (62.8%)**Positive surgical margin**Yes13 (9.5%)No124 (90.5%)[^2]Table 3Postoperative data and complications.Table 3VariablesPatients with PD (n = 137)Post-operative complications-Postoperative pancreatic leak-grade A-grade B-grade C26 (19%)1385-Post-pancreatectomy hemorrhage9 (6.6%)-Biliary leak10 (7.3%)-Delayed Gastric Empty20 (14.6%)-Wound infection26 (19%)-Pulmonary complications12 (8.8%)**Reoperation**Yes14 (10.2%)No123 (89.8%)**ICU stay** (days)mean ± SD3 ± 2(range)(1--9)**Hospital stay** (days)mean ± SD13 ± 3(range)(10--19)**Hospital mortality**9 (6.6%)**Postoperative chemo and/or radiotherapy**Yes81 (59.1%)No56 (40.9%)**Recurrence of tumor**34/128 (26.6%)Clavien Dindo grades of complications040 (29.2%)I30 (21.9%)II28 (20.4%)IIIa13 (9.5%)IIIb11 (8.1%)IVa4 (2.9%)IVb2 (1.5%)V9 (6.5%)[^3]

3.3. Risk factors for survival {#sec3.3}
------------------------------

The median survival across all patients was 33 months; 26 months for patients with PDAC (5-year survival was 24.3%), 37 months for ampullary adenocarcinoma (5-year survival was 42.1%) ([Fig. 2](#fig2){ref-type="fig"}). The 1-, 3-, 5- and 7-year tumor-free survival was 80.1%, 49.3% 31.6%, and 18.6%respectively, while the 1-, 3-, 5- and 7-year overall survival was 84.5%, 57.4%, 35.9% and 20.1% respectively.Fig. 2Kaplan Meier curves for overall survival in patients with PDAC and ampullary adenocarcinoma.Fig. 2

In univariate analysis ([Table 4](#tbl4){ref-type="table"}) the potential risk factors for poor survival were, preoperative comorbidity like hypertension (HTN) or ischemic heart disease (IHD) (P = 0.02), high preoperative carbohydrate antigen 19-9 (CA19-9) (P = 0.04), tumor diameter \> 3 cm (P = 0.001), poor tumor differentiation (P = 0.001), LN invasion (P = 0.04), lymphovascular invasion (P = 0.05), and perineural invasion (P = 0.001). In multivariate analysis ([Table 5](#tbl5){ref-type="table"}) the independent risk factors for poor survival were, large tumor size \> 3 cm (HR: 0.177, 95%CI: 0.084--0.374, P = 0.002), poorly differentiated tumor (HR: 0.059, 95%CI: 0.020--0.0174, P = 0.016), and presence of perineural invasion in the pathological study (HR: 0.101, 95%CI: 0.046--0.224, P = 0.006).Table 4Univariate analysis for potential risk factors for survival.Table 4VariablesNumber of Deaths in PD per cases observed% of DeathsP-value**Age**0.11\>6031/5160.8%≤6040/8646.5%**Gender**0.71Male46/8454.8%Female25/5347.2%**Co-morbidities**-DMYes28/5947.5%0.57No43/7855.1%-HTN/IHDYes28/4266.7%**0.02**No43/9545.3%**Total bilirubin**0.39**\>**10 mg/dl31/5358.5%≤10 mg/dl40/8447.6%**Preoperative biliary drainage**0.95Yes30/5752.6%No41/8051.3%**CA 19-9** (U/ml)**0.04**\>40027/4165.9%≤40044/9645.8%**Pancreatic texture**0.09soft32/7045.7%Firm39/6758.2%**Type of pancreatic reconstruction**0.26Pancreatico-gastrostomy12/2941.4%Pancreatico-jejunostomy59/10854.6%**Vascular reconstruction**0.07Yes12/1770.6%No59/12049.2%**Operative time (min)**0.48\>42043/7954.4%≤42028/5848.3%**Operative blood loss (ml)**0.17\>100033/5658.9%≤100038/8146.9%**Blood transfusion**0.09Yes30/4961.2%no41/8846.6%**Postoperative pancreatic fistula**0.68yes10/2147.6%No61/11652.6%**Maximum tumor diameter (cm)0.001**\>341/5771.9%≤330/8037.5%**Tumor origin**0.79Pancreatic head44/9048.9%Ampullary18/3158.1%Lower CBD6/1060%Duodenum3/650%**Tumor differentiation0.001**Good/moderate43/10341.7%Poor28/3482.4%**Resection margin**0.67R065/12452.4%R1 or R26/1346.2%**Positive lymph nodes0.04**Yes36/5862.1%No35/7944.3%**lymph vascular invasion0.05**Yes38/6261.3%No33/7544%**Perineural invasion0.001**Yes36/5170.6%No35/8640.7%[^4]Table 5Multivariate analysis of independent risk factors for survival in PD.Table 5\
VariableHR95%CI*P*-value**HTN/IHD**0.5790.2691.2460.162**CA19**--**9** \> **400 u/ml**0.9500.5881.5350.833**Tumor size** \> **3 cm**0.1770.0840.374**0.001Poorly differentiated tumor**0.0590.0200.174**0.016Lymph nodes invasion**0.6770.1872.4580.553**Lymph vascular invasion**2.4620.23226.1440.455**Perineural invasion**0.1010.0460.224**0.006**[^5]

4. Discussion {#sec4}
=============

Pancreaticoduodenectomy operation remains the standard curative approach for periampullary tumors. Despite several refinements in the surgical technique with the improvement of postoperative mortality, the long-term prognosis still disappointing with a 5-years survival rate rarely to exceed 20% in some centers. These results raised the enthusiasm to search for the main factors that can improve the prognosis of periampullary tumors with the optimal resection \[[@bib1],[@bib4],[@bib6],[@bib12]\].

In the PAAC the long-term survival rate varies in a wide range related to the different anatomical locations in the periampullary region. El Nakeeb et al., in their study, showed that 5-year survival was 20.6% in PAAC with a median survival of 34 months. The worst prognosis was reported in pancreatic head AC with 5%--20% 5-year survival, and a better prognosis was in ampullary and duodenal AC with 5-year survival 30%--65% \[[@bib20]\]. Also, Zakaria et al., demonstrated that 5-year survival rate in patients with PDAC was 23.4% \[[@bib21]\].

Other studies have reported that there is a comparatively favorable prognosis among PAAC, with 5-year OS rates of 30--70% after radical resection and adjuvant chemo-radiation therapy \[[@bib22], [@bib23], [@bib24]\]. Feretis et al., reported in their study that the overall 1-, 3-, and 5-year survival rates were 79.8%, 42.2%, and 34.9%, respectively \[[@bib25]\], while He et al., demonstrated in their study that 1-, 3-, and 5-year OS rates were 88.2%, 66%, and 53%, respectively \[[@bib26]\]. Our study goes parallel with these previous studies with comparable results.

Serum CA19-9 has manifested as a clinically valuable biomarker of pancreatic cancer, and it has proved that higher serum CA19-9 level preoperatively can predict poorer survival of pancreatic cancer after resection \[[@bib27]\]. However, there were few studies on the prognostic value of CA19-9 in periampullary cancer. Gao et al. have suggested that periampullary cancer patients with preoperative serum CA19-9 \> 35 U/ml are prone to have a poorer survival \[[@bib28]\]. Also, El Nakeeb et al., showed that preoperative serum CA19-9 \> 37 U/ml was associated with a poor survival rate \[[@bib20]\]. In the present study the elevated CA 19-9 (\>400U/ml) had a statistical significance risk for poor survival in univariate analysis, similar to the previous studies.

According to patients with IHD, a previous investigation reported that there was an association between IHD and mortality after PD that did not remain significant in the multivariate model \[[@bib29]\], as seen in our study.

Tumor size is a well-established predictor of survival. In general tumor size \<3 cm has a better prognosis. In some studies it was only significant in univariate analysis \[[@bib30]\]. Other studies, reported that the size of the tumor was independent predictors of survival \[[@bib22]\]. In our study, both univariate and multivariate analysis demonstrated that tumor size \> 3 cm was significantly independent risk factor for poor survival.

Venous reconstruction can be done if there is an invasion of porto-mesentric access to achieve R0 resection with accepted postoperative morbidity and mortality. Some studies showed that the resection margin was an independent risk factor for survival, and R0 achieved significantly better OS \[[@bib6],[@bib7],[@bib20],[@bib31]\]. In contrast, the meta-analysis study by Butturini et al., found that resection margin was not a significant prognostic factor for survival \[[@bib32]\] as seen in our study, it may be due to the difference in the pathological definitions and findings of the resection margin.

Also, tumor differentiation has been reported to be associated with the progression of PAAC. Most studies in the multivariate analysis reported that poor tumor differentiation was a poor prognostic factor for survival \[[@bib26],[@bib33],[@bib34]\], similarly, to what is seen in our series.

Other histopathological characters like lymph node metastasis and lymphovascular invasion should be regarded as an independent predictor of survival and may have therapeutic and prognostic implications for patients \[[@bib11],[@bib33],[@bib34]\]. The poor OS reported in the study by Al-Jumayli et al., was likely due to the high rate of tumor invasion and extension \[[@bib35]\]. As the tumor grows along nerves in the pancreas, it infiltrates distally to follow an arterial channel, reducing the chances of complete microscopic clearance \[[@bib36]\]. Zhao et al., reported in their study that the perineural infiltration was a significant prognostic factor after pancreatic head resection and has been proven to be related to local failure \[[@bib37]\]. The perineural invasion appeared to be the most significantly associated with 1-year mortality \[[@bib10],[@bib12],[@bib38]\]. In our study, the perineural invasion was significantly independent risk factors for poor OS.

Panaro et al., concluded that PDAC is considered a systemic disease, and microvascular invasion is a major prognostic factor after PD as it can lead to distant metastasis, but unfortunately, we cannot predict microvascular invasion in the preoperative image, so it raised the question about the significance of neoadjuvant therapy for all resectable pancreatic cancer, that needs further studies \[[@bib12]\].

The limitations of this study are its retrospective nature and single-center experience that is liable for statistical bias, PD surgery was done by different surgeons but they almost have equal experience, the biological behavior of the different PAAC that may have also racial variations may affect the result between centers and needs further study and there is no complete data about the postoperative adjuvant therapy.

**In conclusion**: It seems from the current study that the predictors of poor long-term survival in patients with PAAC were patients with co-morbidities like HTN or IHD, CA19-9 \> 400U/ml, tumor size \> 3 cm, poor tumor differentiation, LNs invasion, lymphovascular invasion, and Perineural invasion. However, after multivariate analysis tumor size \> 3 cm, poor tumor differentiation, and Perineural invasion were independent risk factors of poor long-term survival. Patients with ampullary AC had better mean survival than patients with pancreatic AC.
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[^1]: PD (pancreaticoduodenectomy), DM (diabetes mellitus), HTN (hypertension), IHD (ischemic heart disease), HCV (hepatitis C virus), HBV (hepatitis B virus), INR (international normalized ratio), CA19.9 (carbohydrate antigen 19.9), CEA (carcinoembryonic antigen), SD (standard deviation).

[^2]: PD (pancreaticoduodenectomy), PPPD (pylorus preserving pancreaticoduodenectomy), CBD (common bile duct), SD (standard deviation). LN (lymph nodes).

[^3]: PD (pancreaticoduodenectomy), ICU (intensive care unit), SD (standard deviation).

[^4]: PD (pancreaticoduodenectomy), DM (diabetes mellitus), HTN (hypertension), IHD (ischemic heart disease), CA19.9 (carbohydrate antigen 19.9), CBD (common bile duct), SD (standard deviation).

[^5]: PD (pancreaticoduodenectomy), HTN (hypertension), IHD (ischemic heart disease), CA19.9 (carbohydrate antigen 19.9).
